News for Adagene Stock (ADAG)

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research • Wednesday

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

GlobeNewsWire • 11/07/24

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

GlobeNewsWire • 10/09/24

Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

GlobeNewsWire • 09/16/24

Are Medical Stocks Lagging Adagene (ADAG) This Year?

Zacks Investment Research • 09/11/24

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September

GlobeNewsWire • 07/12/24

Adagene to Present at Investor Conferences in June

GlobeNewsWire • 05/22/24

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewsWire • 03/29/24

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

GlobeNewsWire • 03/07/24

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024

GlobeNewsWire • 02/27/24

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

GlobeNewsWire • 02/09/24

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

GlobeNewsWire • 01/16/24

Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium

GlobeNewsWire • 01/04/24

Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023

GlobeNewsWire • 11/03/23

Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

GlobeNewsWire • 10/12/23

Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?

Zacks Investment Research • 09/27/23

Adagene to Present at Investor and Scientific Conferences in September

GlobeNewsWire • 09/07/23

Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update

GlobeNewsWire • 08/31/23

Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

GlobeNewsWire • 05/04/23

Adagene Announces Updates to its Board of Directors

GlobeNewsWire • 04/28/23

Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors

GlobeNewsWire • 04/18/23

Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewsWire • 03/28/23

Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April

GlobeNewsWire • 03/14/23

Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board

GlobeNewsWire • 03/06/23

Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial

GlobeNewsWire • 01/09/23